Technetium (^99mTc) sestamibi

Technetium (^99mTc) sestamibi
Clinical data
Trade names	Cardiolite
License data	US FDA: TECHNETIUM_TC-99M_SESTAMIBI_KIT;
Routes of; administration	Intravenous
ATC code	V09GA01 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Bioavailability	NA
Protein binding	1%
Metabolism	Nil
Elimination half-life	Variable
Excretion	Fecal (33%) and renal (27%)
Identifiers
	IUPAC name Hexakis(2-methoxy-2-methylpropylisonitrile); technetium (99mTc);
CAS Number	109581-73-9 ;
PubChem CID	5384;
ChemSpider	396214;
UNII	971Z4W1S09;
KEGG	D01060;
ChEBI	CHEBI:9423;
CompTox Dashboard (EPA)	DTXSID00911248 ;
Chemical and physical data
Formula	C36H66N6O6Tc
Molar mass	777 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [99Tc-5](C#[N+]CC(C)(C)OC)(C#[N+]CC(C)(C)OC)(C#[N+]CC(C)(C)OC)(C#[N+]CC(C)(C)OC)(C#[N+]CC(C)(C)OC)C#[N+]CC(C)(C)OC;
	(verify)

Technetium (^99mTc) sestamibi (INN; commonly sestamibi; USP: technetium Tc 99m sestamibi; trade name Cardiolite) is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six (sesta=6) methoxyisobutylisonitrile (MIBI) ligands. The anion is not defined. The generic drug became available late September 2008. A scan of a patient using MIBI is commonly known as a "MIBI scan".

Sestamibi is taken up by tissues with large numbers of mitochondria and negative plasma membrane potentials.^[1] Sestamibi is mainly used to image the myocardium (heart muscle). It is also used in the work-up of primary hyperparathyroidism to identify parathyroid adenomas, for radioguided surgery of the parathyroid and in the work-up of possible breast cancer.

^ Rizk TH, Nagalli S (5 July 2020). "Technetium (99mTc) Sestamibi". StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. PMID 31985941.

[1] Rizk TH, Nagalli S (5 July 2020). "Technetium (99mTc) Sestamibi". StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. PMID 31985941.

[1]